Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 6/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TET3 | O43151 | 1/20 | 0.47 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.47 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.47 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.47 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216361 | 0.90 | KCNA3 (0.56) | KCNA3OPRL1HTR1ASLC6A4SLC6A3 | |
| Phenoperidine SCHEMBL80415 | 0.84 | KCNA3 (0.83) | KCNA3SLC6A4KMT2A | |
| Phenoperidine SCHEMBL394330 | 0.83 | KCNA3 (0.81) | KCNA3SLC6A4 | |
| SCHEMBL8216333 | 0.83 | OPRM1 (0.67) | KCNA3OPRL1HTR1A | |
| Phenoperidine SCHEMBL1652634 | 0.82 | KCNA3 (0.80) | KCNA3SLC6A4KMT2A | |
| SCHEMBL11716765 | 0.82 | OPRL1 (0.78) | OPRL1 | |
| SCHEMBL22265151 | 0.81 | KCNA3 (0.58) | KCNA3OPRL1 | |
| SCHEMBL8187804 | 0.81 | KCNA3 (0.58) | KCNA3OPRL1 | |
| SCHEMBL11721858 | 0.79 | AKR1C1 (0.54) | KCNA3AKR1C1KMT2ATET3FBXL19 | |
| SCHEMBL9396812 | 0.79 | KMT2A (0.56) | KCNA3AKR1C1KMT2ATET3FBXL19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2022-03-31 | — | — | US | disclosed |
| EP-3914246-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (Institut du Cerveau et de la Moelle Épinière) (FR) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020152212-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) | 2020-07-30 | — | — | WO | disclosed |
| EP-0743940-B1 | NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT | ASTRA AB (SE) | 2000-05-03 | — | — | EP | disclosed |
| US-5968953-A | FOR SIDE EFFECT REDUCTION | ASTRA AB (SE) | 1999-10-19 | — | — | US | disclosed |
| US-5756520-A | N-SUBSTITUTED 4-PHENYL-4-CARBOXAMIDE-PIPERIDINE COMPOUNDS ARE ADMINISTERED EPIDURALLY OR INTRATHECALLY FOR CONTROLLING NERVE BLOCKADE IN HUMANS | ASTRA AB (SE) | 1998-05-26 | — | — | US | disclosed |
| EP-0743940-A1 | NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT | Astra Aktiebolag (SE) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021821-A1 | NEW COMPOUNDS WITH ANALGESIC AND LOCAL ANAESTHETIC EFFECT | ASTRA AKTIEBOLAG (SE) | 1995-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096452-A1 | LOCAL ANESTHETIC FOR THE TREATMENT OF NEUROLOGICAL SYMPTOMS RESULTING FROM BRAIN DYSFUNCTIONS | FABP7, ALB, SLC1A2 | KCNA3 142/4885OPRL1 296/4885HTR1A 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.